JAK3 and Eczematoid dermatitis: Though only tested in adults so far, topical JAK1/JAK3 inhibitor tolfacitinib was better than vehicle alone in a phase IIa clinical trial across all endpoints (Eczema Area and Severity Index [EASI], Investigator’s Global Assessment Score [IGA], body surface area and pruritus; p < 0.001) [58].